What you should know:
1. Mr. d’Esparbes will oversee Progenity’s financial operations.
2. Mr. d’Esparbes touts more than 25 years of financial experience. He most recently was CFO and interim principal executive officer at Innoviva.
3. Progenity CEO and chairman Harry Stylli, PhD, said Mr. d’Esparbes’ strategic planning, risk management and business execution services will be an asset to the company.
4. Progenity is a biotech company creating therapies for women’s health and gastroenterology disorders.
More articles on gastroenterology:
‘A world free of digestive disease’ — AGA President Dr. Hashem El-Serag on the goals for his term
What to know about patient collections & ASC growth from Woodholme Gastroenterology Associates COO Pamela Isabel
Why endoscopy centers should consider employing anesthesiologists now — Attorney Ann Bittinger explains
